Guardant Health
GH
Market cap $2.54B

20.68 USD

-0.94

4.35%

At close Oct 17, 4:00 PM EDT

After hours

20.73

+0.05

0.24%

1 day

-4.35%

5 days

0.78%

1 month

-17.58%

3 months

-36.47%

6 months

26.17%

Year to date

-21.99%

1 year

-24.28%

5 years

-69.48%

About: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Employees: 1,779

Healthcare Medical Laboratories

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 9 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

63% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 43

44% more capital invested

Capital invested by funds: $2.28B [Q1] → $3.29B (+$1.01B) [Q2]

33% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]

11% more funds holding

Funds holding: 252 [Q1] → 279 (+27) [Q2]

2.18% more ownership

Funds ownership: 93.22% [Q1] → 95.39% (+2.18%) [Q2]

9% less repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 90

51% less call options, than puts

Call options by funds: $26.4M | Put options by funds: $53.8M

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$34

64%

upside

Avg. target

$43

107%

upside

High target

$50

142%

upside

9 analyst ratings

9 positive

100%

0 neutral

0%

0 negative

0%

Leerink Partners	142%upside $50	Outperform Maintained	17 Oct 2024
UBS Dan Leonard 43% 1-year accuracy 3 / 7 met price target	93%upside $40	Buy Maintained	21 Aug 2024
Piper Sandler David Westenberg 83% 1-year accuracy 15 / 18 met price target	64%upside $34	Overweight Maintained	13 Aug 2024
Citigroup Patrick Donnelly 67% 1-year accuracy 16 / 24 met price target	118%upside $45	Buy Maintained	8 Aug 2024
TD Cowen Dan Brennan 68% 1-year accuracy 15 / 22 met price target	103%upside $42	Buy Maintained	8 Aug 2024

See Analyst Rankings

Financial journalist opinion

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast wi.

Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024

GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the peer-reviewed journal Nature Medicine published results from the SCRUM-Japan GOZILA study confirming that selecting targeted therapy on the basis of Guardant360® CDx liquid biopsy results may significantly extend survival for patients with advanced cancer. The study, led by a research group out of National Cancer Center Hospital East in Kashiwa, Japan, investigated t.

GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long

Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024. Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial.

Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types

Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a partnership with the Agostino Gemelli University Polyclinic Foundation IRCCS (“Policlinico Gemelli”) to establish an in-house liquid biopsy testing service as a part of its diagnostics services within its hospital system. Leveraging Guardant Health's cutting-edge proprietary digital sequencing platform, this initiative will include on-site analysis of Guardant360® CDx.

Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy

Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. Guardant Health's management is scheduled to participate in a fireside chat on Thursday, September 5th at 11:30 a.m. ET. Interested parties may access live and archived webcasts of the sessions on the “Investors” section of the company website at: www.gua.

Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

The Motley Fool

Why Guardant Health Stock Just Crashed 10%

Guardant Health announced plans to sell stock and raise $400 million in new cash. Guardant burned through nearly $300 million over the past year, so the new fund raise should cover about 16 months of cash burn.

Why Guardant Health Stock Just Crashed 10%

The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Wood added to her positions in Ibotta, Roblox, and Guardant Health on Thursday. Ibotta has taken a hit after its first two quarters as a public company.

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will ring the opening bell at the Nasdaq MarketSite in Times Square, New York on Wednesday, August 28, 2024. “We recently launched Shield, our FDA-approved blood-based screening test, marking a pivotal moment on our journey to conquer cancer with data. We are thrilled to commemorate this important milestone by ringing the Nasdaq bell, nearly six years after w.

Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening

The Motley Fool

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Wood added to her positions in Amazon, Roku, and Guardant Health on Friday. Amazon is working with TikTok to make it easier for influencers on the video app to promote Amazon products, but the stock is still down sharply since posting disappointing second-quarter results this month.

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Guardant Health to Participate in Upcoming Investor Conferences

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences. Canaccord Genuity 44th Annual Growth Conference in Boston, MA Fireside chat on Tuesday, August 13 at 10:30 a.m. ET UBS Genomic Medicine Summit in Dana Point, CA Panel discussion: Future of Cancer Screening on Wednesday, August 14 at 2:45 p.m. PT Interested parties may access live and archived webcasts of.

Guardant Health to Participate in Upcoming Investor Conferences

See News Rankings

Charts implemented using Lightweight Charts™